Thermo Fisher Scientific reports news across scientific instruments, laboratory equipment, diagnostics consumables, life science reagents and pharmaceutical services. Company updates commonly cover operating results, earnings calls, investor presentations and capital deployment through dividends, share repurchases and acquisitions.
Recurring developments also include collaborations tied to laboratory technologies, proteomics, biobank research, analytical instruments and biopharma customer services. Thermo Fisher’s brand portfolio includes Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD, and its completed Clario acquisition added endpoint data solutions for clinical trials to its Laboratory Products and Biopharma Services segment.
Thermo Fisher Scientific Inc. (NYSE: TMO) will have its chairman, president, and CEO present at the BofA Securities Health Care Conference on May 14, 2024. The live webcast will be available on the company's website.
Thermo Fisher Scientific, a global leader in scientific services, extends the expiration of the tender offer for all outstanding common shares and ADSs of Olink. The offer, scheduled to expire on June 18, 2024, aims to acquire Olink Holding AB for $26.00 per share in cash. As of April 30, 2024, approximately 94.3% of outstanding shares have been tendered. Completion of the offer is subject to regulatory approval.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.